Status:
COMPLETED
Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks...
Eligibility Criteria
Inclusion
- Adult patients with Schizophrenia prescribed on Seroquel XR according to the approved product information before inclusion in this non-interventional study
- Signed and dated Patient Informed Consent (ICF)
Exclusion
- Hypersensitivity to the active substance or to any of the excipients of Seroquel XR
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00758251
Start Date
September 1 2008
End Date
March 1 2009
Last Update
December 10 2010
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bauska, Latvia
2
Research SIte
Cēsis, Latvia
3
Research Site
Daugavpils, Latvia
4
Research Site
Dobele, Latvia